MEGL vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

MEGL

42.7
AI Score
VS
HIVE Wins

HIVE

64.0
AI Score

Investment Advisor Scores

MEGL

43score
Recommendation
HOLD

HIVE

64score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric MEGL HIVE Winner
Forward P/E 0 62.8931 Tie
PEG Ratio 0 0 Tie
Revenue Growth 26.7% 73.5% HIVE
Earnings Growth -13.6% -99.9% MEGL
Tradestie Score 42.7/100 64.0/100 HIVE
Profit Margin -72.1% -98.5% MEGL
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

MEGL 1M: -81.7% · 3M: -90.0% HIVE 1M: -26.6% · 3M: -38.8%

Current Technical Phase

MEGL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -30.5%), weak momentum, RSI 16

RSI (14): 16.0 · Price: $0.12

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 33

RSI (14): 33.0 · Price: $1.65

Fundamentals Snapshot

Metric MEGL HIVE
Market Cap — —
Forward P/E 0.0 -3.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.3% 0.7%
Gross Margin 0.7% 0.4%
Operating Margin -1.0% -0.6%
EPS -0.21 -1.53
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.